According to a new report from Intel Market Research, the global Etonogestrel market was valued at USD 852 million in 2024 and is projected to reach USD 1,128 million by 2031, growing at a CAGR of 4.2% during the forecast period (2025-2031).
According to a new report from Intel Market Research, the global Etonogestrel market was valued at USD 852 million in 2024 and is projected to reach USD 1,128 million by 2031, growing at a CAGR of 4.2% during the forecast period (2025-2031). This steady growth is driven by rising demand for hormonal contraceptives, increasing awareness about family planning, and expanding applications in gynecological treatments.
Etonogestrel is a third-generation synthetic progestin derived from 19-nortestosterone, primarily used in contraceptive devices and hormone therapies. As the active metabolite of desogestrel, it demonstrates high progestogenic activity with minimal androgenic effects, making it particularly suitable for long-term contraceptive use.
The compound is best known as the key ingredient in birth control implants (e.g., Nexplanon®) and vaginal rings (e.g., NuvaRing®). These delivery systems provide sustained hormone release, offering effective contraception for periods ranging from three weeks (vaginal rings) to three years (subdermal implants).
Download FREE Sample Report: Etonogestrel Market - View in Detailed Research Report
The increasing preference for LARCs over daily oral contraceptives is a primary growth driver. Unlike short-acting methods that require daily attention, etonogestrel-based implants and rings offer "set-and-forget" contraception with efficacy rates exceeding 99%. Studies show that LARC users experience a 20-fold lower failure rate compared to daily pill users.
Beyond contraception, etonogestrel is gaining traction in treating:
Public health programs in developing nations are increasingly incorporating etonogestrel implants due to their cost-effectiveness and high efficacy. For instance, the UNFPA has distributed over 50 million contraceptive implants globally since 2012, many containing etonogestrel.
While demand grows, several barriers impact market expansion:
The market features a mix of established pharmaceutical companies and API manufacturers:
| Company | Role | Notable Products |
|---|---|---|
| Organon | Brand manufacturer | Nexplanon® implant |
| Aspen API | Active pharmaceutical ingredient supplier | Etonogestrel API |
| Gedeon Richter | Contraceptive manufacturer | Vaginal rings |
The market is poised for innovation with:
Get Full Report Here: Etonogestrel Market - View in Detailed Research Report
Intel Market Research is a leading provider of strategic intelligence, offering actionable insights in biotechnology, pharmaceuticals, and healthcare infrastructure. Our research capabilities include:
Trusted by Fortune 500 companies, our insights empower decision-makers to drive innovation with confidence.
🌐 Website: https://www.intelmarketresearch.com 📞 International: +1 (332) 2424 294 📞 Asia-Pacific: +91 9169164321 🔗 LinkedIn: Follow Us